Genoptix/Novartis
On January 24, 2011, Genoptix, Inc. (Nasdaq: GXDX) announced hat it has entered into a definitive merger agreement to be acquired by Novartis (NYSE: NVS).
Under the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, or total consideration of $470 million in equity and $330 million of enterprise value.
Closing is expected in H111.
Barclays Capital is serving as financial advisor to Genoptix and Cooley LLP is serving as Genoptix' legal advisor.
Under the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25 per share, or total consideration of $470 million in equity and $330 million of enterprise value.
Closing is expected in H111.
Barclays Capital is serving as financial advisor to Genoptix and Cooley LLP is serving as Genoptix' legal advisor.
-
Biocept (BIOC) Announces Samuel D. Riccitelli to Board
-
Biocept Appoints Samuel D. Riccitelli to its Board of Directors
